<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hailey-Hailey disease (benign familial pemphigus)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hailey-Hailey disease (benign familial pemphigus)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hailey-Hailey disease (benign familial pemphigus)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dean Morrell, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H26478746"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hailey-Hailey disease (HHD; MIM #169600), also called benign familial pemphigus or benign chronic pemphigus, is a rare, autosomal dominant disorder that affects the adhesion of epidermal keratinocytes. Initially described by the Hailey brothers in 1939 [<a href="#rid1">1</a>], this intraepidermal blistering disorder is characterized by painful blistering, erosions, maceration, and frequent secondary infection in the flexural areas  (<a class="graphic graphic_picture graphicRef76004" href="/z/d/graphic/76004.html" rel="external">picture 1A</a>). HHD is a chronic condition with multiple recurrences and limited therapeutic options.</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of HHD. Darier disease, a condition that shares many clinical and pathologic features with HHD, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">"Darier disease"</a>.)</p><p class="headingAnchor" id="H26478753"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hailey-Hailey disease (HHD) is a rare disorder. Its prevalence is unknown since many patients lack an accurate diagnosis or do not seek treatment. The age of onset and clinical manifestations of HHD can vary widely within families. First onset after puberty is most common, but presentation during childhood may occur [<a href="#rid2">2</a>]. There is no apparent difference in prevalence among different ethnic groups.</p><p class="headingAnchor" id="H26478760"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Hailey-Hailey disease (HHD) is caused by loss-of-function variants in the <em>ATP2C1</em> gene at 3q22.1, which encodes the adenosine triphosphate (ATP)-powered, magnesium-dependent calcium pump protein hSPCA1. Its function is to maintain normal intracellular concentrations of free calcium (Ca<sup>2+</sup>) by sequestering Ca<sup>2+</sup> into the Golgi apparatus [<a href="#rid3">3</a>].</p><p>HHD is inherited in an autosomal dominant manner with complete penetrance and variable expressivity. Only two-thirds of patients have a family history of HHD; de novo mutations or reduced phenotypic expression in affected family members account for the absence of family history in the remainder. Interfamilial phenotypic variations and the lack of clear genotype-phenotype correlations indicate that environmental and/or other genetic factors may modify the clinical presentation.</p><p>Nearly 180 unique <em>ATP2C1 </em>variants have been reported in families or sporadic patients with HHD [<a href="#rid4">4-6</a>]. Missense, nonsense, frameshift, and splice-site variants have all been reported. <em>ATP2C1 </em>haploinsufficiency is thought to lead to reduced hSPCA1 activity.</p><p>Although the expression of <em>ATP2C1</em> is ubiquitous, HHD is primarily localized to intertriginous areas. Segmental forms showing unilateral or linear distribution represent mosaicism, resulting from postzygotic variants in <em>ATP2C1 </em>(type 1 mosaicism) or postzygotic loss of heterozygosity (loss of the normal allele) combined with a germline pathogenic variant in <em>ATP2C1 </em>(type 2 mosaicism) [<a href="#rid7">7-9</a>].</p><p>Calcium homeostasis in keratinocytes is involved in epidermal differentiation, barrier repair, cell-cell adhesion, and keratinocyte motility. Although the precise mechanism is incompletely understood, the genetic defect results in altered cellular connections within desmosomes and adherens junctions of the epidermis (acantholysis), secondary to high cytosolic calcium levels.</p><p>However, other factors may have a role in the development of the clinical manifestations of HHD, including oxidative stress and microRNAs [<a href="#rid10">10,11</a>]. MicroRNAs are small, noncoding RNAs involved in post-transcriptional regulation of gene expression. The microRNA miR-125b, which regulates the expression of factors implicated in keratinocyte proliferation and differentiation, appears to be upregulated in keratinocytes from patients with HHD [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H26478767"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H73555732"><span class="h2">Typical presentation</span><span class="headingEndMark"> — </span>The onset of Hailey-Hailey disease (HHD) typically occurs in the second and third decades of life. The clinical manifestations primarily involve the flexural areas in a symmetric fashion (groin, axillae, lateral neck, submammary region, and perineum). Mucosal involvement is rare.</p><p>Flaccid vesicles on erythematous to normal skin are the first manifestation and are often not noticed. Large, macerated, exudative plaques of superficial erosions with crusting are usually seen at the time of the diagnosis  (<a class="graphic graphic_picture graphicRef76004 graphicRef61689 graphicRef74552 graphicRef80862" href="/z/d/graphic/76004.html" rel="external">picture 1A-D</a>). Further progression to large, vegetative, malodorous plaques with painful fissures can occur. Flexural disease may be disabling, especially if the groin is involved.</p><p>Longitudinal, white bands of the nails have been described in approximately 70 percent of patients with HHD and can be a clue to the diagnosis [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H163982653"><span class="h2">Segmental or localized Hailey-Hailey disease</span><span class="headingEndMark"> — </span>Localized or linear segmental forms of HHD, the latter also known as "relapsing linear acantholytic dermatosis," have been described [<a href="#rid13">13-15</a>]. They present as unilateral, linear, patchy, or otherwise localized lesions. Linear lesions are often distributed along the Blaschko lines, representing patterns of skin and appendage cell migration during embryogenesis. In very rare cases, segmental HHD lesions may appear at an early age in individuals who later develop typical, symmetrical, bilateral HHD lesions [<a href="#rid7">7,14</a>].</p><p>These clinical phenotypes are considered mosaic forms of HHD, resulting from postzygotic variants in <em>ATP2C1</em> or loss of heterozygosity at the <em>ATP2C1</em> locus. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H20008536"><span class="h2">Clinical course</span><span class="headingEndMark"> — </span>HHD has a remitting and relapsing course with a substantial impact on quality of life [<a href="#rid16">16</a>]. When the inflammation remits and lesions heal, postinflammatory hyperpigmentation is a common sequela. Exacerbating factors include sweating, friction, ultraviolet radiation, and cutaneous infections [<a href="#rid12">12</a>].</p><p>Colonization and secondary infection with bacteria (<em>Staphylococcus</em>, <em>Streptococcus</em>) and fungi (dermatophytes, <em>Candida</em>) are common and a frequent cause of the persistence or exacerbation of lesions [<a href="#rid17">17-19</a>]. Vegetations and malodor are signs of bacterial or fungal overgrowth. Bacterial and fungal cultures should be performed during relapses to determine appropriate antibiotic or antifungal treatment.</p><p class="headingAnchor" id="H23965479"><span class="h2">Risk of squamous cell carcinoma</span><span class="headingEndMark"> — </span>There are anecdotal reports of squamous cell carcinomas arising in vulvar and penile lesions of HHD [<a href="#rid20">20-22</a>]. However, it is unclear whether the chronic impairment of the epidermal barrier in HHD increases the risk of infection from oncogenic strains of human papillomavirus [<a href="#rid23">23</a>]. In a mouse model, <em>ATP2C1</em> mutations induced the development of squamous cell tumors in the absence of skin manifestations of HHD [<a href="#rid24">24</a>]. Melanoma and other cancers have also been reported in patients with HHD [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H26478774"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of Hailey-Hailey disease (HHD) is suggested by the clinical finding of characteristic, macerated erosions limited to intertriginous areas without satellite lesions, especially if there is a history of similar clinical manifestations in other family members.</p><p class="headingAnchor" id="H3804557027"><span class="h2">Skin biopsy and histopathology</span><span class="headingEndMark"> — </span>A skin biopsy of lesional skin for routine histopathologic examination and direct immunofluorescence staining is needed to confirm the diagnosis.</p><p>Histopathologic findings include widespread loss of cohesion among suprabasal keratinocytes (acantholysis), resulting in suprabasal clefts and acantholytic vesicles and bullae. Areas of partial acantholysis form layers of intraepidermal and suprabasal, detached keratinocytes with the appearance of a "dilapidated brick wall"  (<a class="graphic graphic_picture graphicRef75555" href="/z/d/graphic/75555.html" rel="external">picture 2</a>). Dyskeratosis (abnormal keratinization) is usually mild.</p><p>The papillary dermis contains a sparse, perivascular, lymphocytic infiltrate with scattered eosinophils. Neutrophils may be seen in the vesicles and in the parakeratotic crust [<a href="#rid26">26</a>].</p><p>In contrast with autoimmune pemphigus, direct immunofluorescence is negative in HHD. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p class="headingAnchor" id="H2060503153"><span class="h2">Molecular diagnosis</span><span class="headingEndMark"> — </span>Molecular testing of peripheral blood DNA for variants in <em>ATP2C1</em> that cause HHD is clinically available, although it is generally not required for the diagnosis. Referral for genetic services can help facilitate counseling, discussion of pros and cons of genetic testing, interpretation of the results, and implications for the family. The American College of Medical Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=15463" target="_blank">website</a> can be searched by zip code or city and state to find local genetics services. (See <a class="local">'Genetic counseling'</a> below.)</p><p class="headingAnchor" id="H26478790"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Several dermatologic diseases may have clinical features and distribution similar to Hailey-Hailey disease (HHD) [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Darier disease</strong> – Flexural lesions of Darier disease are clinically difficult to differentiate from HHD. However, Darier disease is characterized by greasy, hyperkeratotic papules involving seborrheic areas (eg, scalp, ears, central chest, and upper back) and by a distinctive nail dystrophy  (<a class="graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef81865" href="/z/d/graphic/70000.html" rel="external">picture 3A-C</a>). Histologically, acantholysis is more widespread in HHD than in Darier disease, whereas dyskeratosis (abnormal, premature keratinization of keratinocytes, which appear as "corps ronds" or "grains") predominates in Darier disease. (See  <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">"Darier disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Papular acantholytic dyskeratosis of the vulva </strong>– Papular acantholytic dyskeratosis (PAD) of the vulva is a rare, chronic disorder presenting in young adult and older females as small, pruritic papules over the vulva and inguinal folds. PAD is a noninherited disorder and is thought to be a mosaic form of Darier disease [<a href="#rid28">28</a>]. However, there are reports of familial cases of PAD, suggesting that PAD may be an allelic variant of HHD [<a href="#rid29">29-31</a>]. The histopathologic findings in PAD are characteristically a combination of those seen in both Darier disease and HHD (ie, suprabasal clefting and acantholysis, dyskeratotic cells resembling corps ronds and grains). (See  <a class="medical medical_review" href="/z/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Galli-Galli disease</strong> – Galli-Galli disease is a rare, autosomal dominant disorder considered an acantholytic variant of Dowling-Degos disease, a reticulated pigmentary disorder of the skin. Galli-Galli disease is caused by missense variants in the <em>KRT5</em> gene and presents with reticulated hyperpigmentation and keratotic, papular lesions involving the major flexural areas. Histologically, there are elongated, finger-like strands of keratinocytes extending into the papillary dermis; hyperpigmentation of the rete ridges; multiple foci of acantholysis; and dyskeratotic cells. (See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Diffuse reticular hyperpigmentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus</strong> – Vegetating, flexural lesions occur in pemphigus vegetans, an uncommon variant of pemphigus vulgaris  (<a class="graphic graphic_picture graphicRef60187" href="/z/d/graphic/60187.html" rel="external">picture 4</a>). A positive direct immunofluorescence confirms the diagnosis of pemphigus. (See  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seborrheic</strong> <strong>dermatitis </strong>– The involvement of intertriginous areas is possible in seborrheic dermatitis  (<a class="graphic graphic_picture graphicRef53407 graphicRef68137" href="/z/d/graphic/53407.html" rel="external">picture 5A-B</a>). However, erythematous plaques and/or yellowish, greasy scales are typically seen on the scalp, eyebrows, or nasolabial folds  (<a class="graphic graphic_picture graphicRef54173 graphicRef76985 graphicRef59104" href="/z/d/graphic/54173.html" rel="external">picture 6A-C</a>). (See  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inverse</strong> <strong>psoriasis</strong> – Psoriasis of the intertriginous areas usually lacks scaling and may be difficult to differentiate from other causes of intertrigo  (<a class="graphic graphic_picture graphicRef79274 graphicRef78531 graphicRef76200 graphicRef50615 graphicRef56110" href="/z/d/graphic/79274.html" rel="external">picture 7A-E</a>). However, the presence of psoriatic plaques in nonflexural areas, involvement of the umbilicus, and pitting of nail plates allow for the correct diagnosis  (<a class="graphic graphic_picture graphicRef70962 graphicRef73527" href="/z/d/graphic/70962.html" rel="external">picture 8A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Inverse (intertriginous) psoriasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intertrigo </strong>– Erythematous, macerated plaques and erosions with peripheral scaling and satellite papulopustules are characteristic of candidal intertrigo  (<a class="graphic graphic_picture graphicRef72073 graphicRef78179" href="/z/d/graphic/72073.html" rel="external">picture 9A-B</a>). Tinea cruris usually presents with erythematous, scaling plaques with sharp margins, without vesicles or erosions and few satellite lesions  (<a class="graphic graphic_picture graphicRef71067" href="/z/d/graphic/71067.html" rel="external">picture 10</a>). Bacterial colonization, which is common in individuals with obesity, may cause maceration. (See  <a class="medical medical_review" href="/z/d/html/115366.html" rel="external">"Intertrigo"</a> and  <a class="medical medical_review" href="/z/d/html/115364.html" rel="external">"Approach to the patient with an intertriginous skin disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrasma</strong> – Erythrasma is caused by the overgrowth of <em>Corynebacterium minutissimum</em>, a component of the normal skin flora. It presents with well-defined, erythematous/brown patches in the axillae, inframammary region, or groin  (<a class="graphic graphic_picture graphicRef80242 graphicRef59529 graphicRef51713" href="/z/d/graphic/80242.html" rel="external">picture 11A-C</a>). A coral-red fluorescence under Wood's lamp examination will confirm the diagnosis  (<a class="graphic graphic_picture graphicRef62143" href="/z/d/graphic/62143.html" rel="external">picture 12</a>). (See  <a class="medical medical_review" href="/z/d/html/4031.html" rel="external">"Erythrasma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granular parakeratosis </strong>– Granular parakeratosis is a rare disorder characterized by hyperkeratotic, reddish-brown plaques occurring in intertriginous areas  (<a class="graphic graphic_picture graphicRef108742" href="/z/d/graphic/108742.html" rel="external">picture 13</a>). The diagnosis is based upon the histologic finding of keratohyalin granules within the corneocytes, resulting in a granular appearance of the stratum corneum. (See  <a class="medical medical_review" href="/z/d/html/99982.html" rel="external">"Granular parakeratosis"</a>.)</p><p></p><p class="headingAnchor" id="H1578623156"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no specific therapy for Hailey-Hailey disease (HHD). The therapeutic approach to HHD involves the control of exacerbating factors, secondary infections, and cutaneous inflammation. Because of the rarity of the disease, evidence of efficacy for topical or systemic therapies is mainly based upon small observational studies, case reports, and clinical experience [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3023347860"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Since heat, moisture, and friction provoke cutaneous flares of HHD, all patients with HHD will benefit from measures aimed at reducing sweating, friction, and bacterial colonization in the involved areas:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of body weight, if appropriate</p><p class="bulletIndent1"><span class="glyph">●</span>Use of lightweight, loose clothing</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of very hot environments</p><p class="bulletIndent1"><span class="glyph">●</span>Use of absorbent pads in skin folds to reduce moisture</p><p></p><p>Open, crusted, macerated, and malodorous lesions can be treated with diluted bleach (0.5 cup or 120 mL of 6% bleach in a full bathtub of water [40 gallons or 150 L] or 1 tsp or 5 mL of bleach in one gallon of water [3.8 L]). This may be applied as baths, soaks, or compresses on a regular basis (eg, two to three times per week) to decrease staphylococcal carriage.</p><p>Alternatively, antibacterial washes, such as <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> gluconate 4% wash, may be used on a daily basis. Topical compresses of <a class="drug drug_general" data-topicid="95641" href="/z/d/drug information/95641.html" rel="external">aluminum acetate</a> solution at a 1:40 dilution, applied intermittently for 5 to 10 minutes, may also be beneficial for macerated lesions.</p><p>Bacterial and fungal cultures of the involved sites are useful to determine appropriate antibiotic or antifungal treatment.</p><p class="headingAnchor" id="H2643378031"><span class="h2">Patients with mild disease</span></p><p class="headingAnchor" id="H3374865667"><span class="h3">Topical therapies</span><span class="headingEndMark"> — </span>For patients with mild disease, we suggest topical antimicrobials and topical corticosteroids or topical calcineurin inhibitors as first-line treatment. Topical therapies are aimed at controlling the overgrowth of microbial flora and reducing inflammation. The efficacy of these treatments has not been evaluated in clinical trials, and their use is mainly based on small observational studies and case reports and clinical experience [<a href="#rid12">12,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical antibiotics</strong> − <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> 1% lotion or cream, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> 0.1% cream, or <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> 2% cream are applied to the affected areas two to four times per day for two to four weeks. In children, ointment preparations are generally better tolerated than lotions or creams.</p><p></p><p class="bulletIndent1">Patients with frequent exacerbations due to heavy microbial colonization may need systemic treatment with oral antibiotics or antifungals, guided by the culture's results. (See <a class="local">'Systemic therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical antifungals</strong> − <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">Ketoconazole</a> 2% cream or another azole cream may be helpful for patients with fungal colonization. Antifungal creams are applied twice daily for two to four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical corticosteroids </strong>− Short courses of moderate- to high-potency topical corticosteroids (groups 3 and 4  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>)) may be used in conjunction with topical antimicrobials to treat episodes of exacerbation. Topical corticosteroids are applied twice a day for five to seven days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical calcineurin inhibitors</strong> − <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> ointment may be an alternative to topical corticosteroids for long-term control of inflammation. Tacrolimus 0.1% ointment is applied twice a day until resolution of the lesions.</p><p></p><p>There are isolated reports of successful treatment with topical <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">calcipotriol</a> [<a href="#rid34">34-36</a>], topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [<a href="#rid37">37</a>], and topical <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H2203744409"><span class="h2">Patients with severe disease</span></p><p class="headingAnchor" id="H2809118480"><span class="h3">Intralesional botulinum toxin type A</span><span class="headingEndMark"> — </span>For patients with extensive or severe disease, intermittent injections of botulinum toxin aimed at reducing sweating and maceration can be an adjunct to topical antimicrobial and anti-inflammatory therapies. Botulinum toxin type A is injected into the axillae or inguinal folds with the same technique used in the treatment of hyperhidrosis [<a href="#rid39">39-43</a>] (see  <a class="medical medical_review" href="/z/d/html/5567.html" rel="external">"Primary focal hyperhidrosis", section on 'Botulinum toxin'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of six cases, botulin toxin 500 units was injected into the axillae or inguinal folds, following the technique used in the treatment of hyperhidrosis [<a href="#rid41">41</a>]. There were no flares four months after treatment in one patient and no flares at two months in two additional cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label study, 30 patients (26 with HHD and 4 with Darier disease) received intradermal injections of botulinum toxin (50 units per 100 cm<sup>2</sup>, up to a total of 200 units)<sup> </sup>in selected areas of moderate to severe disease [<a href="#rid44">44</a>]. Of the 26 patients with HHD, 15 (58 percent) showed a sustained improvement at six months, whereas 11 experienced a relapse (9 at one month).</p><p></p><p class="headingAnchor" id="H26544173"><span class="h3">Systemic therapies</span><span class="headingEndMark"> — </span>Intermittent courses of oral antibiotics are occasionally used to control episodes of increased disease activity. The choice of antibiotic is determined by the patient's culture results. Some advocate use of tetracyclines because of their additional anti-inflammatory effect [<a href="#rid45">45</a>].</p><p>Other systemic therapies anecdotally reported as beneficial include cyclosporin 2.5 to 3.5 mg/kg per day [<a href="#rid46">46-48</a>]; <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> 15 mg/week [<a href="#rid49">49,50</a>]; <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> 25 mg/day [<a href="#rid51">51,52</a>]; <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a> [<a href="#rid53">53</a>]; <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> 1 mg/day [<a href="#rid54">54</a>]; oral <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid55">55</a>]; <a class="drug drug_general" data-topicid="122889" href="/z/d/drug information/122889.html" rel="external">afamelanotide</a> 16 mg in a sustained-release, resorbable implant formulation [<a href="#rid56">56</a>]; oral vitamin D supplementation [<a href="#rid57">57</a>]; <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> 300 mg subcutaneously every other week [<a href="#rid58">58,59</a>]; <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> [<a href="#rid60">60,61</a>]; and <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a> [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H2639599774"><span class="h3">Surgical or destructive therapies</span><span class="headingEndMark"> — </span>Surgical and destructive methods have been used in a few patients with recalcitrant HHD and include [<a href="#rid63">63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical excision [<a href="#rid64">64,65</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Carbon dioxide laser or 595 nm pulsed dye laser ablation [<a href="#rid66">66-71</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Argon plasma coagulation [<a href="#rid72">72</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cold atmospheric plasma [<a href="#rid73">73</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Dermabrasion [<a href="#rid74">74-76</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Photodynamic therapy [<a href="#rid77">77-80</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Electron beam radiation [<a href="#rid81">81,82</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial radiation therapy [<a href="#rid83">83</a>]</p><p></p><p>Drawbacks of surgical and destructive therapies include long healing time; pain; scarring; and uncertain, long-term benefit.</p><p class="headingAnchor" id="H3647134965"><span class="h3">Emerging medical therapies</span><span class="headingEndMark"> — </span>Serendipitous, patient-reported observations have drawn attention to two promising therapies for HHD: oral <a class="drug drug_general" data-topicid="10122" href="/z/d/drug information/10122.html" rel="external">magnesium chloride</a> supplementation and low-dose oral <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>. Although promising, the efficacy of these treatments needs to be confirmed in additional studies before they can be recommended for the treatment of severe, recalcitrant HHD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium chloride</strong> – In three patients, <a class="drug drug_general" data-topicid="10122" href="/z/d/drug information/10122.html" rel="external">magnesium chloride</a> taken once daily as an oral solution containing approximately 300 mg of elemental magnesium induced a rapid improvement in HHD lesions, with nearly complete resolution in four weeks [<a href="#rid84">84,85</a>]. No adverse effects were reported. In one patient, the electrolyte serum levels, including calcemia and magnesemia, were normal after 12 months of continued treatment [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">Although the mechanism of action of <a class="drug drug_general" data-topicid="10122" href="/z/d/drug information/10122.html" rel="external">magnesium chloride</a> supplementation in HHD has not been clarified, one hypothesis is that it may affect the altered intracellular calcium homeostasis in HHD keratinocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Naltrexone</strong> – <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">Naltrexone</a>, an opioid antagonist used in the treatment of alcohol and opioid dependence, has been found to be effective in inducing the resolution of HHD lesions in some patients [<a href="#rid86">86-91</a>]. The mechanism of action of naltrexone in HHD is unclear. One hypothesis is that its effect may be due to its anti-inflammatory properties, as well as to some influence on intracellular calcium homeostasis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one report, three patients with recalcitrant HHD were treated with low-dose <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> hydrochloride given orally at a dose of 1.5 to 3 mg per day after stopping all other topical or systemic therapies [<a href="#rid87">87</a>]. All three patients achieved an 80 to 90 percent clinical improvement, defined as resolution of erosions, improvement in erythema, and decrease in tenderness and discomfort, after three to four months of treatment with naltrexone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another report, three patients older than 50 years with longstanding HHD were treated with oral <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> 3 mg and up to 4.5 mg per day [<a href="#rid86">86</a>]. Erosions began to heal from the periphery within one to two weeks of starting treatment and were completely resolved at four months. No major adverse effects were reported with low-dose naltrexone. Minor adverse effects included headache, gastrointestinal symptoms, and vivid dreams. In both reports, discontinuing low-dose naltrexone resulted in a relapse of HHD within a few days, which resolved within a week of restarting therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another report of three patients, complete resolution was achieved in one patient taking oral <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> 4.5 mg per day after 18 months of continued treatment. A rapid, complete resolution occurred in one patient after a two-month treatment with a higher dose of naltrexone (12.5 mg per day), whereas no response was observed in another patient treated with naltrexone 50 mg per day for concurrent brachioradialis pruritus [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a Spanish series of 14 patients (12 with moderate or severe disease) treated with low-dose <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> and followed up for a median of 34 weeks, six patients showed no improvement, six patients had an initial improvement but relapsed, and only two patients showed a sustained response [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In two case reports, combination treatment with low-dose <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> and oral magnesium resulted in substantial improvement of longstanding and recalcitrant HHD [<a href="#rid92">92,93</a>].</p><p></p><p class="headingAnchor" id="H1785844435"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>For patients with Hailey-Hailey disease (HHD), offering referral for genetics services to discuss inheritance pattern, recurrence risk, pros and cons of genetic testing, and reproductive options (eg, preimplantation genetic testing) is appropriate. (See <a class="local">'Molecular diagnosis'</a> above.)</p><p>Because HHD is an autosomal dominant disorder, an affected person will have up to a one in two chance of having a child who is also affected. Prenatal diagnosis is possible for future children in a family when the causative mutation in a parent is known.</p><p class="headingAnchor" id="H9328049"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Hailey-Hailey disease (HHD) has a chronic, relapsing, and remitting course. The long-term benefits of medical and/or surgical approaches to HHD are uncertain, and recurrence is common. Patients with HHD have a normal life expectancy, although with significantly impaired quality of life.</p><p class="headingAnchor" id="H26478811"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Hailey-Hailey disease (HHD), also called benign familial pemphigus, is a rare, autosomal dominant genodermatosis caused by variants in the <em>ATP2C1 </em>gene, encoding an adenosine triphosphate (ATP)-powered calcium pump, which result in altered intercellular connections (acantholysis) in the epidermis. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – HHD typically presents in the second or third decades of life with blistering, erosions, maceration, and frequent secondary infection in the flexural areas  (<a class="graphic graphic_picture graphicRef76004 graphicRef61689 graphicRef74552 graphicRef80862" href="/z/d/graphic/76004.html" rel="external">picture 1A-D</a>). HHD has a remitting and relapsing course; exacerbating factors include sweating, friction, ultraviolet radiation, and infection. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of HHD is suggested by the clinical findings. A skin biopsy for histopathologic examination and direct immunofluorescence staining is needed to confirm the diagnosis and rule out other dermatoses with similar clinical findings and lesion distribution. Molecular testing of peripheral blood cells for causative DNA mutations in the <em>ATP2C1</em> gene is clinically available. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Molecular diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There is no specific therapy for HHD. Its management involves the control of exacerbating factors, secondary infections, and cutaneous inflammation (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with mild disease, we suggest topical antimicrobials and topical corticosteroids or topical calcineurin inhibitors as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical antibiotics, such as <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> 1% lotion or cream, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> 0.1% cream, or <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> 2% cream, are applied two to four times per day for two to four weeks. Short courses (five to seven days) of moderate- to high-potency topical corticosteroids (groups 3 and 4  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>)) may be used in conjunction with topical antimicrobials to treat episodes of exacerbations. (See <a class="local">'Patients with mild disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with extensive or severe disease, we suggest intermittent injections of botulinum toxin (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Botulin toxin reduces sweating and maceration and may be added to topical antimicrobial and anti-inflammatory therapies. For the rare cases of severe and recalcitrant disease, oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, or <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a> (not available in the United States) are options to be tried prior to destructive approaches with laser and/or surgery. (See <a class="local">'Patients with severe disease'</a> above and <a class="local">'Surgical or destructive therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hailey H, Hailey H. Familial benign chronic pemphigus. Arch Dermatol 1939; 39:679.</a></li><li><a class="nounderline abstract_t">Xu Z, Zhang L, Xiao Y, et al. A case of Hailey-Hailey disease in an infant with a new ATP2C1 gene mutation. Pediatr Dermatol 2011; 28:165.</a></li><li><a class="nounderline abstract_t">Hu Z, Bonifas JM, Beech J, et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet 2000; 24:61.</a></li><li><a class="nounderline abstract_t">Nellen RG, Steijlen PM, van Steensel MA, et al. Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease. Hum Mutat 2017; 38:343.</a></li><li class="breakAll">Leiden Open Variation Database. The ATP2C1 gene homepage. www.lovd.nl/ATP2C1 (Accessed on August 16, 2017).</li><li><a class="nounderline abstract_t">Wang Z, Li L, Sun L, et al. Review of 52 cases with Hailey-Hailey disease identified 25 novel mutations in Chinese Han population. J Dermatol 2019; 46:1024.</a></li><li><a class="nounderline abstract_t">Poblete-Gutiérrez P, Wiederholt T, König A, et al. Allelic loss underlies type 2 segmental Hailey-Hailey disease, providing molecular confirmation of a novel genetic concept. J Clin Invest 2004; 114:1467.</a></li><li><a class="nounderline abstract_t">Hwang LY, Lee JB, Richard G, et al. Type 1 segmental manifestation of Hailey-Hailey disease. J Am Acad Dermatol 2003; 49:712.</a></li><li><a class="nounderline abstract_t">Vakilzadeh F, Kolde G. Relapsing linear acantholytic dermatosis. Br J Dermatol 1985; 112:349.</a></li><li><a class="nounderline abstract_t">Manca S, Magrelli A, Cialfi S, et al. Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. Exp Dermatol 2011; 20:932.</a></li><li><a class="nounderline abstract_t">Cialfi S, Oliviero C, Ceccarelli S, et al. Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease. Br J Dermatol 2010; 162:518.</a></li><li><a class="nounderline abstract_t">Burge SM. Hailey-Hailey disease: the clinical features, response to treatment and prognosis. Br J Dermatol 1992; 126:275.</a></li><li><a class="nounderline abstract_t">Katzman JA, Chavan R, Holliday AC, et al. Mosaic variant in ATP2C1 presenting as relapsing linear acantholytic dermatosis. Br J Dermatol 2020; 183:155.</a></li><li><a class="nounderline abstract_t">García-Morales I, Requena-Caballero L, Happle R, Torrelo A. Segmental Hailey-Hailey disease of the vulva. Pediatr Dermatol 2018; 35:e398.</a></li><li><a class="nounderline abstract_t">Lipoff JB, Mudgil AV, Young S, et al. Acantholytic dermatosis of the crural folds with ATP2C1 mutation is a possible variant of Hailey-Hailey Disease. J Cutan Med Surg 2009; 13:151.</a></li><li><a class="nounderline abstract_t">Gisondi P, Sampogna F, Annessi G, et al. Severe impairment of quality of life in Hailey-Hailey disease. Acta Derm Venereol 2005; 85:132.</a></li><li><a class="nounderline abstract_t">Flint ID, Spencer DM, Wilkin JK. Eczema herpeticum in association with familial benign chronic pemphigus. J Am Acad Dermatol 1993; 28:257.</a></li><li><a class="nounderline abstract_t">Chen MY, Chiu HC, Su LH, et al. Presence of human papillomavirus type 6 DNA in the perineal verrucoid lesions of Hailey-Hailey disease. J Eur Acad Dermatol Venereol 2006; 20:1356.</a></li><li><a class="nounderline abstract_t">Chan CC, Thong HY, Chan YC, Liao YH. Human papillomavirus type 5 infection in a patient with Hailey-Hailey disease successfully treated with imiquimod. Br J Dermatol 2007; 156:579.</a></li><li><a class="nounderline abstract_t">Holst VA, Fair KP, Wilson BB, Patterson JW. Squamous cell carcinoma arising in Hailey-Hailey disease. J Am Acad Dermatol 2000; 43:368.</a></li><li><a class="nounderline abstract_t">Cockayne SE, Rassl DM, Thomas SE. Squamous cell carcinoma arising in Hailey-Hailey disease of the vulva. Br J Dermatol 2000; 142:540.</a></li><li><a class="nounderline abstract_t">Chun SI, Whang KC, Su WP. Squamous cell carcinoma arising in Hailey-Hailey disease. J Cutan Pathol 1988; 15:234.</a></li><li><a class="nounderline abstract_t">Ochiai T, Honda A, Morishima T, et al. Human papillomavirus types 16 and 39 in a vulval carcinoma occurring in a woman with Hailey-Hailey disease. Br J Dermatol 1999; 140:509.</a></li><li><a class="nounderline abstract_t">Okunade GW, Miller ML, Azhar M, et al. Loss of the Atp2c1 secretory pathway Ca(2+)-ATPase (SPCA1) in mice causes Golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes. J Biol Chem 2007; 282:26517.</a></li><li><a class="nounderline abstract_t">Mohr MR, Erdag G, Shada AL, et al. Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers. Arch Dermatol 2011; 147:211.</a></li><li class="breakAll">Weedon D. Disorders of epidermal maturation and keratinization. In: Weedon's Skin Pathology, 3rd ed, David Weedon (Ed), Elsevier Health, 2010.</li><li><a class="nounderline abstract_t">Wolf R, Oumeish OY, Parish LC. Intertriginous eruption. Clin Dermatol 2011; 29:173.</a></li><li><a class="nounderline abstract_t">Knopp EA, Saraceni C, Moss J, et al. Somatic ATP2A2 mutation in a case of papular acantholytic dyskeratosis: mosaic Darier disease. J Cutan Pathol 2015; 42:853.</a></li><li><a class="nounderline abstract_t">Pernet C, Bessis D, Savignac M, et al. Genitoperineal papular acantholytic dyskeratosis is allelic to Hailey-Hailey disease. Br J Dermatol 2012; 167:210.</a></li><li><a class="nounderline abstract_t">Yu WY, Ng E, Hale C, et al. Papular acantholytic dyskeratosis of the vulva associated with familial Hailey-Hailey disease. Clin Exp Dermatol 2016; 41:628.</a></li><li><a class="nounderline abstract_t">Vodo D, Malchin N, Furman M, et al. Identification of a recurrent mutation in ATP2C1 demonstrates that papular acantholytic dyskeratosis and Hailey-Hailey disease are allelic disorders. Br J Dermatol 2018; 179:1001.</a></li><li><a class="nounderline abstract_t">Arora H, Bray FN, Cervantes J, Falto Aizpurua LA. Management of familial benign chronic pemphigus. Clin Cosmet Investig Dermatol 2016; 9:281.</a></li><li><a class="nounderline abstract_t">Galimberti RL, Kowalczuk AM, Bianchi O, et al. Chronic benign familial pemphigus. Int J Dermatol 1988; 27:495.</a></li><li><a class="nounderline abstract_t">Bianchi L, Chimenti MS, Giunta A. Treatment of Hailey-Hailey disease with topical calcitriol. J Am Acad Dermatol 2004; 51:475.</a></li><li><a class="nounderline abstract_t">Di Guida A, Fabbrocini G, Patruno C, Napolitano M. Hailey-Hailey disease treated successfully with calcipotriol plus betamethasone dipropionate aerosol foam: A case report. Dermatol Ther 2021; 34:e14654.</a></li><li><a class="nounderline abstract_t">Rajpara SM, King CM. Hailey-Hailey disease responsive to topical calcitriol. Br J Dermatol 2005; 152:816.</a></li><li><a class="nounderline abstract_t">Dammak A, Camus M, Anyfantakis V, Guillet G. Successful treatment of Hailey-Hailey disease with topical 5-fluorouracil. Br J Dermatol 2009; 161:967.</a></li><li><a class="nounderline abstract_t">Edminister JR, Patel HA, Pixley JN, et al. Improvement of Hailey-Hailey Disease With Topical Cinacalcet, 3%, Ointment. JAMA Dermatol 2023; 159:669.</a></li><li><a class="nounderline abstract_t">Lapiere JC, Hirsh A, Gordon KB, et al. Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. Dermatol Surg 2000; 26:371.</a></li><li><a class="nounderline abstract_t">Bessa GR, Grazziotin TC, Manzoni AP, et al. Hailey-Hailey disease treatment with Botulinum toxin type A. An Bras Dermatol 2010; 85:717.</a></li><li><a class="nounderline abstract_t">Koeyers WJ, Van Der Geer S, Krekels G. Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey-Hailey disease. J Dermatolog Treat 2008; 19:251.</a></li><li><a class="nounderline abstract_t">Bagherani N, Smoller BR. The efficacy of botulinum toxin type A in the treatment of Hailey-Hailey disease. Dermatol Ther 2016; 29:394.</a></li><li><a class="nounderline abstract_t">Dousset L, Pham-Ledard A, Doutre MS, et al. [Treatment of Hailey-Hailey disease with botulinic toxin: A retrospective study of 8 cases]. Ann Dermatol Venereol 2017; 144:599.</a></li><li><a class="nounderline abstract_t">Dreyfus I, Maza A, Rodriguez L, et al. Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study. Orphanet J Rare Dis 2021; 16:93.</a></li><li><a class="nounderline abstract_t">Le Saché-de Peufeilhoux L, Raynaud E, Bouchardeau A, et al. Familial benign chronic pemphigus and doxycycline: a review of 6 cases. J Eur Acad Dermatol Venereol 2014; 28:370.</a></li><li><a class="nounderline abstract_t">Berth-Jones J, Smith SG, Graham-Brown RA. Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin. Clin Exp Dermatol 1995; 20:70.</a></li><li><a class="nounderline abstract_t">Nanda A, Khawaja F, Harbi R, et al. Benign familial pemphigus (Hailey-Hailey disease) responsive to low dose cyclosporine. Indian J Dermatol Venereol Leprol 2010; 76:422.</a></li><li><a class="nounderline abstract_t">Varada S, Ramirez-Fort MK, Argobi Y, Simkin AD. Remission of refractory benign familial chronic pemphigus (hailey-hailey disease) with the addition of systemic cyclosporine. J Cutan Med Surg 2015; 19:163.</a></li><li><a class="nounderline abstract_t">Fairris GM, White JE, Leppard BJ, Goodwin PG. Methotrexate for intractable benign familial chronic pemphigus. Br J Dermatol 1986; 115:640.</a></li><li><a class="nounderline abstract_t">Vilarinho C, Ventura F, Brito C. Methotrexate for refractory Hailey-Hailey disease. J Eur Acad Dermatol Venereol 2010; 24:106.</a></li><li><a class="nounderline abstract_t">Hunt MJ, Salisbury EL, Painter DM, Lee S. Vesiculobullous Hailey-Hailey disease: successful treatment with oral retinoids. Australas J Dermatol 1996; 37:196.</a></li><li><a class="nounderline abstract_t">Berger EM, Galadari HI, Gottlieb AB. Successful treatment of Hailey-Hailey disease with acitretin. J Drugs Dermatol 2007; 6:734.</a></li><li><a class="nounderline abstract_t">Sárdy M, Ruzicka T. Successful therapy of refractory Hailey-Hailey disease with oral alitretinoin. Br J Dermatol 2014; 170:209.</a></li><li><a class="nounderline abstract_t">Kaniszewska M, Rovner R, Arshanapalli A, Tung R. Oral glycopyrrolate for the treatment of Hailey-Hailey disease. JAMA Dermatol 2015; 151:328.</a></li><li><a class="nounderline abstract_t">Bedi M, Taylor AL. Recalcitrant Hailey-Hailey disease responds to oral tacrolimus and botulinum toxin type A. Cutis 2015; 96:E14.</a></li><li><a class="nounderline abstract_t">Biolcati G, Aurizi C, Barbieri L, et al. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clin Exp Dermatol 2014; 39:168.</a></li><li><a class="nounderline abstract_t">Megna M, Scalvenzi M, Russo D, et al. Hailey-Hailey disease successfully treated with vitamin D oral supplementation. Dermatol Ther 2019; 32:e12767.</a></li><li><a class="nounderline abstract_t">Alzahrani N, Grossman-Kranseler J, Swali R, et al. Hailey-Hailey disease treated with dupilumab: a case series. Br J Dermatol 2021; 185:680.</a></li><li><a class="nounderline abstract_t">Alamon-Reig F, Serra-García L, Bosch-Amate X, et al. Dupilumab in Hailey-Hailey disease: a case series. J Eur Acad Dermatol Venereol 2022; 36:e776.</a></li><li><a class="nounderline abstract_t">Kieffer J, Le Duff F, Montaudié H, et al. Treatment of Severe Hailey-Hailey Disease With Apremilast. JAMA Dermatol 2018; 154:1453.</a></li><li><a class="nounderline abstract_t">Yoto A, Makino T, Mizawa M, et al. Two cases of Hailey-Hailey disease effectively treated with apremilast and a review of reported cases. J Dermatol 2021; 48:1945.</a></li><li><a class="nounderline abstract_t">Adamson SR, Higgins CL, Veysey E. Hailey-Hailey disease (benign familial pemphigus) responsive to treatment with ocrelizumab for multiple sclerosis. Br J Dermatol 2023; 189:232.</a></li><li><a class="nounderline abstract_t">Farahnik B, Blattner CM, Mortazie MB, et al. Interventional treatments for Hailey-Hailey disease. J Am Acad Dermatol 2017; 76:551.</a></li><li><a class="nounderline abstract_t">Menz P, Jackson IT, Connolly S. Surgical control of Hailey-Hailey disease. Br J Plast Surg 1987; 40:557.</a></li><li><a class="nounderline abstract_t">Aubert JP, Folchetti G, Berbis P, Magalon G. [Surgical treatment of Hailey-Hailey disease or benign chronic familial pemphigus. Apropos of a case of submammary localization]. Ann Chir Plast Esthet 1993; 38:568.</a></li><li><a class="nounderline abstract_t">Don PC, Carney PS, Lynch WS, et al. Carbon dioxide laserabrasion: a new approach to management of familial benign chronic pemphigus (Hailey-Hailey disease). J Dermatol Surg Oncol 1987; 13:1187.</a></li><li><a class="nounderline abstract_t">Kukova G, Homey B, Bruch-Gerharz D, Diedrichson E. [Familial benign chronic pemphigus (Hailey-Hailey disease): successful treatment with carbon dioxide laser]. Hautarzt 2011; 62:258.</a></li><li><a class="nounderline abstract_t">McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease. J Am Acad Dermatol 1990; 23:893.</a></li><li><a class="nounderline abstract_t">Hunt KM, Jensen JD, Walsh SB, et al. Successful treatment of refractory Hailey-Hailey disease with a 595-nm pulsed dye laser: a series of 7 cases. J Am Acad Dermatol 2015; 72:735.</a></li><li><a class="nounderline abstract_t">Falto-Aizpurua LA, Griffith RD, Yazdani Abyaneh MA, Nouri K. Laser therapy for the treatment of Hailey-Hailey disease: a systematic review with focus on carbon dioxide laser resurfacing. J Eur Acad Dermatol Venereol 2015; 29:1045.</a></li><li><a class="nounderline abstract_t">García-Zamora E, López-Estebaranz JL, Dradi GG, Álvarez-Fernández JG. Carbon Dioxide Laser Treatment in Hailey-Hailey Disease. Dermatol Surg 2022; 48:146.</a></li><li><a class="nounderline abstract_t">Stolze I, Hamm H, Weyandt GH. Segmental multilayered argon plasma coagulation: effective therapy option for perianal and scrotal Hailey-Hailey disease. Colorectal Dis 2011; 13:802.</a></li><li><a class="nounderline abstract_t">Isbary G, Morfill G, Zimmermann J, et al. Cold atmospheric plasma: a successful treatment of lesions in Hailey-Hailey disease. Arch Dermatol 2011; 147:388.</a></li><li><a class="nounderline abstract_t">LeBlanc KG Jr, Wharton JB, Sheehan DJ. Refractory Hailey-Hailey disease successfully treated with sandpaper dermabrasion. Skinmed 2011; 9:263.</a></li><li><a class="nounderline abstract_t">Hamm H, Metze D, Bröcker EB. Hailey-Hailey disease. Eradication by dermabrasion. Arch Dermatol 1994; 130:1143.</a></li><li><a class="nounderline abstract_t">Kirtschig G, Gieler U, Happle R. Treatment of Hailey-Hailey disease by dermabrasion. J Am Acad Dermatol 1993; 28:784.</a></li><li><a class="nounderline abstract_t">Ruiz-Rodriguez R, Alvarez JG, Jaén P, et al. Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease). J Am Acad Dermatol 2002; 47:740.</a></li><li><a class="nounderline abstract_t">Fernández Guarino M, Ryan AM, Harto A, et al. Experience with photodynamic therapy in Hailey-Hailey disease. J Dermatolog Treat 2008; 19:288.</a></li><li><a class="nounderline abstract_t">Lobato-Berezo A, Imbernón-Moya A, Aguilar-Martínez A. Refractory Hailey-Hailey Disease That Responded Well to Photodynamic Therapy. Actas Dermosifiliogr 2015; 106:852.</a></li><li><a class="nounderline abstract_t">Alsahli M, Debu A, Girard C, et al. Is photodynamic therapy a relevant therapeutic option in refractory benign familial pemphigus (Hailey-Hailey disease)? A series of eight patients. J Dermatolog Treat 2017; 28:678.</a></li><li><a class="nounderline abstract_t">Graham PM, Melkonian A, Fivenson D. Familial benign chronic pemphigus (Hailey-Hailey disease) treated with electron beam radiation. JAAD Case Rep 2016; 2:159.</a></li><li><a class="nounderline abstract_t">Leung N, Cardones AR, Larrier N. Long-term improvement of recalcitrant Hailey-Hailey disease with electron beam radiation therapy: Case report and review. Pract Radiat Oncol 2018; 8:e259.</a></li><li><a class="nounderline abstract_t">Wulf HC, Wiegell SR. Treatment of Familial Benign Chronic Pemphigus With Superficial Radiotherapy. JAMA Dermatol 2022; 158:283.</a></li><li><a class="nounderline abstract_t">Barde NG, Mishra DB, Ingole SO. Oral magnesium chloride: A novel approach in the management of Hailey-Hailey disease. Indian J Dermatol Venereol Leprol 2017; 83:259.</a></li><li><a class="nounderline abstract_t">Borghi A, Rimessi A, Minghetti S, et al. Efficacy of magnesium chloride in the treatment of Hailey-Hailey disease: from serendipity to evidence of its effect on intracellular Ca(2+) homeostasis. Int J Dermatol 2015; 54:543.</a></li><li><a class="nounderline abstract_t">Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone. JAMA Dermatol 2017; 153:1018.</a></li><li><a class="nounderline abstract_t">Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease). JAMA Dermatol 2017; 153:1015.</a></li><li><a class="nounderline abstract_t">Cao S, Lilly E, Chen ST. Variable Response to Naltrexone in Patients With Hailey-Hailey Disease. JAMA Dermatol 2018; 154:362.</a></li><li><a class="nounderline abstract_t">Riquelme-Mc Loughlin C, Riera-Monroig J, Morgado-Carrasco D, et al. Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): A case series. J Am Acad Dermatol 2019; 81:644.</a></li><li><a class="nounderline abstract_t">Sousa Gomes M, Araújo Pereira J, Trocado V, et al. Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review. Arch Gynecol Obstet 2020; 302:1081.</a></li><li><a class="nounderline abstract_t">Vyas HR, Shah SR, Patel HS, Shah BJ. Recalcitrant cases of Hailey-Hailey disease successfully managed with low-dose naltrexone. Int J Dermatol 2023; 62:e149.</a></li><li><a class="nounderline abstract_t">Alajmi A, Jfri A, Lovett A. Hailey-Hailey disease treated successfully with naltrexone and magnesium. JAAD Case Rep 2019; 5:760.</a></li><li><a class="nounderline abstract_t">Lim D, Belisle A, Davar S. Improvement in Hailey-Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: A case report. SAGE Open Med Case Rep 2020; 8:2050313X20984121.</a></li></ol></div><div id="topicVersionRevision">Topic 15463 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Familial benign chronic pemphigus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20403116" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A case of Hailey-Hailey disease in an infant with a new ATP2C1 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10615129" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28035777" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28035777" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31435946" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Review of 52 cases with Hailey-Hailey disease identified 25 novel mutations in Chinese Han population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545997" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Allelic loss underlies type 2 segmental Hailey-Hailey disease, providing molecular confirmation of a novel genetic concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512922" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Type 1 segmental manifestation of Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3978039" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Relapsing linear acantholytic dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21913998" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903178" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554604" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hailey-Hailey disease: the clinical features, response to treatment and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31605620" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mosaic variant in ATP2C1 presenting as relapsing linear acantholytic dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30168169" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Segmental Hailey-Hailey disease of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19426624" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acantholytic dermatosis of the crural folds with ATP2C1 mutation is a possible variant of Hailey-Hailey Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15823906" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Severe impairment of quality of life in Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432925" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Eczema herpeticum in association with familial benign chronic pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062074" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Presence of human papillomavirus type 6 DNA in the perineal verrucoid lesions of Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300256" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Human papillomavirus type 5 infection in a patient with Hailey-Hailey disease successfully treated with imiquimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10901726" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Squamous cell carcinoma arising in Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735968" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Squamous cell carcinoma arising in Hailey-Hailey disease of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3183139" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Squamous cell carcinoma arising in Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233276" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Human papillomavirus types 16 and 39 in a vulval carcinoma occurring in a woman with Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597066" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Loss of the Atp2c1 secretory pathway Ca(2+)-ATPase (SPCA1) in mice causes Golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339448" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339448" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396557" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intertriginous eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154588" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Somatic ATP2A2 mutation in a case of papular acantholytic dyskeratosis: mosaic Darier disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22229453" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genitoperineal papular acantholytic dyskeratosis is allelic to Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028372" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Papular acantholytic dyskeratosis of the vulva associated with familial Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29944739" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Identification of a recurrent mutation in ATP2C1 demonstrates that papular acantholytic dyskeratosis and Hailey-Hailey disease are allelic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27695354" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Management of familial benign chronic pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3065260" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Chronic benign familial pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337998" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of Hailey-Hailey disease with topical calcitriol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33300647" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hailey-Hailey disease treated successfully with calcipotriol plus betamethasone dipropionate aerosol foam: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840130" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hailey-Hailey disease responsive to topical calcitriol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663874" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful treatment of Hailey-Hailey disease with topical 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37043228" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Improvement of Hailey-Hailey Disease With Topical Cinacalcet, 3%, Ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759827" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21152802" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hailey-Hailey disease treatment with Botulinum toxin type A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18629693" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26970226" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The efficacy of botulinum toxin type A in the treatment of Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669425" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : [Treatment of Hailey-Hailey disease with botulinic toxin: A retrospective study of 8 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33602313" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23106313" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Familial benign chronic pemphigus and doxycycline: a review of 6 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671404" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20657133" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Benign familial pemphigus (Hailey-Hailey disease) responsive to low dose cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25775626" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Remission of refractory benign familial chronic pemphigus (hailey-hailey disease) with the addition of systemic cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790441" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Methotrexate for intractable benign familial chronic pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19627406" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Methotrexate for refractory Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961587" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vesiculobullous Hailey-Hailey disease: successful treatment with oral retinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763599" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Successful treatment of Hailey-Hailey disease with acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23937159" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Successful therapy of refractory Hailey-Hailey disease with oral alitretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651401" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Oral glycopyrrolate for the treatment of Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26761940" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Recalcitrant Hailey-Hailey disease responds to oral tacrolimus and botulinum toxin type A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24256215" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30291662" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hailey-Hailey disease successfully treated with vitamin D oral supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33971025" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hailey-Hailey disease treated with dupilumab: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35734956" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dupilumab in Hailey-Hailey disease: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30304341" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of Severe Hailey-Hailey Disease With Apremilast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34569085" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Two cases of Hailey-Hailey disease effectively treated with apremilast and a review of reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37002729" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hailey-Hailey disease (benign familial pemphigus) responsive to treatment with ocrelizumab for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27745906" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Interventional treatments for Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3318985" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Surgical control of Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944232" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : [Surgical treatment of Hailey-Hailey disease or benign chronic familial pemphigus. Apropos of a case of submammary localization].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3117856" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Carbon dioxide laserabrasion: a new approach to management of familial benign chronic pemphigus (Hailey-Hailey disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21424889" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : [Familial benign chronic pemphigus (Hailey-Hailey disease): successful treatment with carbon dioxide laser].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2123894" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773417" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Successful treatment of refractory Hailey-Hailey disease with a 595-nm pulsed dye laser: a series of 7 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25418614" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Laser therapy for the treatment of Hailey-Hailey disease: a systematic review with focus on carbon dioxide laser resurfacing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34772828" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Carbon Dioxide Laser Treatment in Hailey-Hailey Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478009" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Segmental multilayered argon plasma coagulation: effective therapy option for perianal and scrotal Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482888" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cold atmospheric plasma: a successful treatment of lesions in Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21980715" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Refractory Hailey-Hailey disease successfully treated with sandpaper dermabrasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8085869" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hailey-Hailey disease. Eradication by dermabrasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496429" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of Hailey-Hailey disease by dermabrasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399767" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608733" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Experience with photodynamic therapy in Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387451" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Refractory Hailey-Hailey Disease That Responded Well to Photodynamic Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301978" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Is photodynamic therapy a relevant therapeutic option in refractory benign familial pemphigus (Hailey-Hailey disease)? A series of eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27222876" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Familial benign chronic pemphigus (Hailey-Hailey disease) treated with electron beam radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29907515" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Long-term improvement of recalcitrant Hailey-Hailey disease with electron beam radiation therapy: Case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35019942" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Treatment of Familial Benign Chronic Pemphigus With Superficial Radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28164896" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Oral magnesium chloride: A novel approach in the management of Hailey-Hailey disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25430969" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy of magnesium chloride in the treatment of Hailey-Hailey disease: from serendipity to evidence of its effect on intracellular Ca(2+) homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28768313" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28768314" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29344611" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Variable Response to Naltrexone in Patients With Hailey-Hailey Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002846" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32776297" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35780232" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Recalcitrant cases of Hailey-Hailey disease successfully managed with low-dose naltrexone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31516990" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Hailey-Hailey disease treated successfully with naltrexone and magnesium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33489235" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Improvement in Hailey-Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: A case report.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
